Cytokine News and Research

RSS

SARS-CoV-2 can directly invade human kidney cells, research shows

Up to 25% of patients' COVID-19 cases involve acute kidney injury—the kidneys' equivalent of a heart attack.

29 Nov 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021

Efficacy and safety of an RBD-based recombinant protein COVID-19 vaccine

A study developed a protein-based subunit vaccine, PHH-1V, that consisted of a recombinant RBD fusion heterodimer of the alpha) and beta variants of SARS-CoV-2.

26 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Maternal-fetal interface yields intriguing clues to how it battles SARS-CoV-2

Scientists have hypothesized that the number of immune cells and the amount of cytokines produced in response to SARS-CoV-2 infection in pregnant women change in accordance with the timing of maternal infection in pregnancy. This study is available on the bioRxiv* preprint server.

24 Nov 2021

Study identifies small RNA molecule as a therapeutic target for COPD

Research led by the Centenary Institute and University of Technology Sydney (UTS) has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment for chronic obstructive pulmonary disease (COPD).

24 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

Indian researchers determine the magnitude, quality, and persistence of cellular and humoral memory responses after vaccination with BBV152/Covaxin.

23 Nov 2021

Study shows SARS-CoV-2 can infect and replicate in human iPSC-derived neurons

In a study recently published on the bioRxiv preprint server, researchers attempted to further increase the scope of previous studies in examining SARS-CoV-2 infection of human CNS resident cells.

22 Nov 2021

Human lung airway-on-a-chip faithfully recapitulates cystic fibrosis pathology

The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices.

21 Nov 2021

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.

19 Nov 2021

Severe COVID-19 patients have significantly higher NK and T cell frequency

A new study published in the open-access journal Cells aimed to clarify the role of NK and T cell subsets in SARS-CoV-2 infection in hospitalized COVID-19 patients to unravel their potential association with disease severity.

18 Nov 2021

Tea and coffee consumption associated with lower risk of stroke and dementia

Researchers investigate the impact of coffee and tea separately and in combination on the risk of stroke and dementia.

18 Nov 2021

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

18 Nov 2021